Linked Life Data

7041040

Source:http://linkedlifedata.com/resource/pubmed/id/7041040

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1982-6-14
pubmed:abstractText
The anti-vertigo activity of flunarizine has been evaluated in a 16-week double-blind placebo-controlled cross-over trial involving 41 patients. After a 4-week open running-in treatment with 10 mg flunarizine daily, the 40 responders were either further treated with flunarizine--at the same dose--or given matching placebo. After another 6 weeks, they were switched to the alternative medication. Severity of vertigo, and frequency and duration of the attacks were quickly and significantly reduced with the open flunarizine dose. Continuation of the drug further produced a slight improvement whereas switching over to the placebo resulted in a significant deterioration of the patients' condition. Tinnitus seemed to be less responsive to treatment. The level of untoward effects (sedation) was low and similar for both medications.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0301-1569
pubmed:author
pubmed:issnType
Print
pubmed:volume
44
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
72-80
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1982
pubmed:articleTitle
Flunarizine in vertigo. A double-blind placebo-controlled cross-over evaluation of a constant-dose schedule.
pubmed:publicationType
Journal Article, Clinical Trial